Stake saleHealthcare & Life Sciences
Motilal Oswal fund sells 2% of Molbio
By Abha Lohia · Editor ·
Molbio Diagnostics: revenue and funding and every story →
Stake saleGoaFounded 2000
- Molbio Diagnostics is a Goa-based maker of molecular diagnostic tests and devices, now listed on the stock exchanges
- A fund managed by Motilal Oswal Alternates sold about 2% of the company for ₹306 crore in open market trades on Wednesday
- HDFC Mutual Fund bought roughly 2% at the same price, and the fund had sold a larger block worth ₹394 crore a week earlier
What happened
- Business Excellence Trust III sold 23.28 lakh shares
- Average price was about ₹1,315 a share
- Sale value came to ₹306.26 crore
- HDFC Mutual Fund picked up 23 lakh shares for ₹302.45 crore
- The stock closed about 4% higher at ₹1,309.45
Why it matters
- The fund held about 11.5% as of August, so it is trimming after listing
- Large buyers stepping in shows institutional demand for the stock
- A similar ₹394 crore sale last week points to a steady exit
The business
- Molbio makes Truenat, a portable machine that runs lab-grade DNA tests (real-time PCR, a method that copies genetic material to detect germs) for infectious diseases such as TB.
- It also sells a breast-screening device, a portable X-ray reading tool and digital pathology systems.
- Buyers are government health programmes, aid agencies, hospitals and diagnostic labs, mostly in places with few central labs.
- It earns by selling the machines and, more importantly, the test kits used with them; most revenue comes from TB kits sold to Indian and overseas public health programmes.
- It is used in 90+ countries, with over 8,293 Truenat systems installed in India.
- It is based in Verna, Goa, and does research through its subsidiary Bigtec Labs.
The founders
- Leads commercial strategy, fundraising and government partnerships at Molbio.
- Directs the micro-PCR chip design and test development behind the Truenat platform.
Who put in money
- Motilal Oswal Alternates Existing investor — Sold through its Business Excellence Trust III fund
In numbers
₹1,445.69 croreOperating revenue · FY2026
₹836.56 croreOperating revenue · FY2024
90+Countries served · 2026
8,293Truenat systems in India · 2026
Earlier rounds
- 2021-05 · Series B · $19.2 million
- 2022-09 · Growth round · $85 million
- 2026-08-07 · Pre-IPO anchor round · Rs 281.5 crore
- 2026-08 · IPO · Rs 939.7 crore
Up against
AbbottbioMérieuxQIAGENThermo Fisher ScientificMeril
The numbers around it
Molbio Diagnostics has 1 funding rounds in StopDown's archive.
| When | Round | Amount | Led by |
|---|---|---|---|
| 7 August 2026 | Pre-IPO anchor round | ₹281.5 Cr | Undefined |
Healthcare & Life Sciences in October 2026: 20 rounds with a disclosed amount, $242 million in all; the biggest was Linux Laboratories ($70M). Every sector this year →
Read next
IPOMolbio Diagnostics lists at 21% premium on exchangesMolbio Diagnostics makes point-of-care molecular diagnostic systems for multiple diseasesFundingAugust AI raises $12M for US expansionAugust AI offers an AI health assistant that answers medical questions through WhatsApp and a mobile appFundingVitusCare raises $3 million Series BVitusCare runs dialysis units inside partner hospitals, which keeps costs low, and has grown from 22 to over 60 centres
Everything on Molbio Diagnostics → · All startup news on 1 October 2026 →
Is this Molbio Diagnostics? Get your “Featured on StopDown” badge →